A Study of Daratumumab plus EPOCH Chemotherapy to Treat Plasmablastic Lymphoma

Share
Print

Full Title

A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma (AMC 105)

Purpose

Plasmablastic lymphoma is a type of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study is to determine if adding daratumumab to a standard chemotherapy regimen (DA-EPOCH) is a safe way to increase the effectiveness of treatment in people with plasmablastic lymphoma.   

Daratumumab targets cells that produce the protein CD38, which is found at high levels in plasmablastic lymphoma cells. It is used to treat multiple myeloma. Its use in this study is considered investigational. EPOCH is a chemotherapy regimen that combines the drugs etoposide, vincristine, cyclophosphamide, doxorubicin, and prednisone and is used to treat lymphoma. Daratumumab and EPOCH are given intravenously (by vein).

 

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have plasmablastic lymphoma that has not yet been treated.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 646-608-3727.

Protocol

20-033

Phase

I

Investigator

Co-Investigators